Compare MCHX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHX | SCLX |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 55.1M |
| IPO Year | 2003 | N/A |
| Metric | MCHX | SCLX |
|---|---|---|
| Price | $1.79 | $6.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.9K | ★ 113.7K |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,291,000.00 | N/A |
| Revenue This Year | $5.37 | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.32 | $4.20 |
| 52 Week High | $2.14 | $34.27 |
| Indicator | MCHX | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 41.80 |
| Support Level | $1.54 | $5.72 |
| Resistance Level | $1.92 | $7.77 |
| Average True Range (ATR) | 0.10 | 0.81 |
| MACD | -0.00 | -0.25 |
| Stochastic Oscillator | 61.54 | 6.69 |
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.